Ad hoc Announcement in Accordance with §15 WpHG Continuation of the SAPHIRE Study into the Second Recruitment Stage
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, has announced the decision to advance the Phase II Hodgkin’s lymphoma (HL) SAPHIRE study with the HDAC inhibitor resminostat into the second Simon stage of patient recruitment.
This decision is based on the analysis of radiological imaging data from patients treated in the first Simon stage through an independent central assessment committee, which confirmed the achievement of the clinical activity requirements for the advancement of the trial.
4SC announced that the first patient had been treated in this trial on January 12, 2010. The Phase II SAPHIRE trial will continue into its second stage of patient recruitment and final results are expected, as planned, in the second half of 2011.
This decision is based on the analysis of radiological imaging data from patients treated in the first Simon stage through an independent central assessment committee, which confirmed the achievement of the clinical activity requirements for the advancement of the trial.
4SC announced that the first patient had been treated in this trial on January 12, 2010. The Phase II SAPHIRE trial will continue into its second stage of patient recruitment and final results are expected, as planned, in the second half of 2011.
